Skip to content

ChemMedChem

ISSN 1860-7187

2 papers in the library · publishing 2026

Papers

We Licked the Toads so You Don’t Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5‐Methoxy‐ N , N ‐Dimethyltryptamine

ChemMedChem February 25, 2026 Anton A. Homon, Jaxon Laramie, John J. Hayward et al.

Bufotenin and 5-MeO-DMT are potent psychedelics found in plants and toad secretions. Although used in traditional medicine, 20th-century prohibition slowed research into their therapeutic potential for psychological disorders and inflammatory and neurodegenerative diseases. Recent global trends toward legalization have increased clinical and preclinical studies, creating demand for large amounts of these compounds that are not commercially available on scale. The first bufotenin synthesis was reported in 1935, and new syntheses continue to appear in the 2020s. This review collates and compares all extant academic and patent syntheses as of fall 2024, enabling researchers to identify the most appropriate route. Outstanding challenges for reducing commercial-scale production costs are highlighted.

A Novel Tertiary Carbamate Prodrug Strategy to Overcome Metabolic Barriers in Oral Ketamine Delivery.

ChemMedChem January 1, 2026 Juulia Järvinen, Santosh Kumar Adla, Janne Tampio et al.

A ketamine prodrug designed with a tyrosine methyl ester and a tertiary carbamate linker aimed to improve oral absorption and reduce abuse potential. The prodrug showed moderate solubility and stability at physiological pH but did not release ketamine in enzyme-containing media. In mice, oral administration led to rapid metabolic conversion but only low levels of ketamine in plasma, liver, and brain, resulting in very low oral bioavailability. The design does not sufficiently promote ketamine release or systemic exposure, indicating that further structural optimization is needed for therapeutically meaningful delivery.